endpts.com·Jun 4, 2026
Ona Therapeutics, a Barcelona-based ADC biotech company, has successfully raised $86.6 million in a Series B funding round to advance two of its antibody-drug conjugate candidates into clinical trials.
Ona Therapeutics' recent $86.6 million Series B funding round signifies a strong investment signal in the ADC (antibody-drug conjugates) biotech space, aimed at advancing their clinical pipeline. This substantial capital injection highlights the growing interest and potential for ADCs in precision medicine, making it an opportune area for further exploration and potential investment within the healthtech and biotech sectors.